Left ventricular hypertrophy: a pressure-independent cardiovascular risk factor.
Left ventricular hypertrophy (LVH), an increase in the muscle mass of the left ventricle, has been identified as a powerful risk factor for future cardiovascular morbidity and mortality. The risk of acute myocardial infarction, congestive heart failure, sudden death, and other cardiovascular events increases sixfold to eightfold with the occurrence of LVH. The increase in myocardial mass lowers coronary reserve and enhances cardiac oxygen requirements, gives rise to ventricular ectopy, and impairs left ventricular filling and contractility. Hypertension, obesity, advanced age, valvular heart disease, and other pathologic disorders that cause an increase in the hemodynamic burden can lead to LVH. LVH and its sequelae can be reduced by specific antihypertensive therapy, but despite these promising findings, future epidemiologic studies are necessary to document the clinical benefits of a reduction in LVH.
Messerli
F H
FH
Department of Internal Medicine, Ochsner Clinic, New Orleans, Louisiana 70121.
Ketelhut
R
R
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000209:etiology; D005260:Female; D006331:Heart Diseases / Q000209:etiology*; D006333:Heart Failure / Q000209:etiology; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000150:complications* / Q000188:drug therapy / Q000209:etiology; D008297:Male; D017202:Myocardial Ischemia / Q000209:etiology; D012307:Risk Factors; D012737:Sex Factors
D000959:Antihypertensive Agents